Elucid has developed machine learning models that can interpret a patient’s risk of stroke or cardiovascular events from angiography images.

Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.

While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker